Giant Cell Arteritis Drugs Market Outlook: Competitor Analysis and Forecast until 2031 - Biogen, Novartis AG & Aark Pharmaceuticals.

The global giant cell arteritis drugs market reached US$ 933.2 million in 2023 and is expected to reach US$ 1859.5 million by 2031 growing with a CAGR of 9% during the forecast period 2024-2031.

DataM Intelligence has published a new research report on "Giant Cell Arteritis Drugs Market Size 2024". The report explores comprehensive and insightful Information about various key factors like Segmentation, CAGR, business revenue competitive positioning of key companies, investigating elements such as product offerings, pricing strategies, financial performance, product portfolios, growth initiatives, and geographical reach. The purpose of this report is to provide a telescopic view of the current market size by value and volume, opportunities, and development status.

Get a Free Sample Research PDF - https://datamintelligence.com/download-sample/giant-cell-arteritis-drugs-market

Giant Cell Arteritis (GCA), also known as temporal arteritis, is an inflammatory disease that primarily affects the large and medium-sized arteries, especially those in the head and neck. It is characterized by the infiltration of giant cells in the arterial wall, leading to vessel wall damage and potential complications, such as vision loss. The management of GCA typically involves the use of medications aimed at reducing inflammation and preventing complications.

Key Developments:

➤ AbbVie's SELECT-GCA Study:

✔ In April 2024, AbbVie announced positive top-line results from the SELECT-GCA study, a Phase 3 multicenter, randomized, double-blind, placebo-controlled trial.

✔ The study evaluated upadacitinib (RINVOQ; 15 mg, once daily) in combination with a 26-week steroid taper regimen.
The primary endpoint was achieved, showing sustained remission from week 12 through week 52 in adults with giant cell arteritis (GCA). This marks a significant advancement in GCA treatment options, indicating that upadacitinib may effectively control the disease while allowing for corticosteroid tapering.

➤ EULAR Recommendations for Tocilizumab:

✔ In March 2023, the European League Against Rheumatism (EULAR) updated its guidelines, recommending tocilizumab for patients with new or relapsing giant cell arteritis.

✔ The updated consensus statement advises the use of weekly tocilizumab at a dose of 162 mg in conjunction with glucocorticoids, which should eventually be tapered. This reaffirms tocilizumab's role as an essential therapy for GCA, particularly in managing flare-ups and preventing disease progression.

Research Process:

Both primary and secondary data sources have been used in the global Giant Cell Arteritis Drugs Market research report. During the research process, a wide range of industry-affecting factors are examined, including governmental regulations, market conditions, competitive levels, historical data, market situation, technological advancements, upcoming developments, in related businesses, as well as market volatility, prospects, potential barriers, and challenges.

List of the Key Players in the Giant Cell Arteritis Drugs Market:

Genentech, Inc., F. Hoffmann-La Roche Ltd, Biogen, Novartis AG, Aark Pharmaceuticals, Aetna Inc., Sartorius AG, Fresenius Kabi USA, Bio-Rad Laboratories, Inc and CELLTRION INC.

Segment Covered in the Giant Cell Arteritis Drugs Market:

By Drug Type: Corticosteroids, Immune-suppressing Agents, Anti Coagulants, Biologics, Others.

By Route of Administration: Oral, Intravenous, Subcutaneous,Others.

By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies.

Regional Analysis:

The global Giant Cell Arteritis Drugs Market report focuses on six major regions: North America, Latin America, Europe, Asia Pacific, the Middle East, and Africa.

Get Customization in the report as per your requirements: https://datamintelligence.com/customize/giant-cell-arteritis-drugs-market

Regional Analysis:

The global Giant Cell Arteritis Drugs Market report focuses on six major regions: North America, Latin America, Europe, Asia Pacific, the Middle East, and Africa. The report offers detailed insight into new product launches, new technology evolutions, innovative services, and ongoing R&D. The report discusses a qualitative and quantitative market analysis, including PEST analysis, SWOT analysis, and Porter's five force analysis. The Giant Cell Arteritis Drugs Market report also provides fundamental details such as raw material sources, distribution networks, methodologies, production capacities, industry supply chain, and product specifications.

**The full version of the report includes an in-depth analysis of emerging players and startups, which will provide valuable insights into the evolving market landscape and key strategies being adopted**

Chapter Outline:

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: key insights, key emerging trends, etc.

Chapter 3: Manufacturers competitive analysis, detailed analysis of Giant Cell Arteritis Drugs manufacturers competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product revenue, gross margin, product introduction, recent development, etc.

Chapter 5 & 6: Revenue of Giant Cell Arteritis Drugs in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 7: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 8: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: The main points and conclusions of the report.

Have any Query? Talk to our Expert @ https://www.datamintelligence.com/enquiry/giant-cell-arteritis-drugs-market

Frequently Asked Questions

Q1) How Big is the Giant Cell Arteritis Drugs Market?

A) The global giant cell arteritis drugs market reached US$ 933.2 million in 2023 and is expected to reach US$ 1859.5 million by 2031 growing with a CAGR of 9% during the forecast period 2024-2031.

Q2) Who are the key players of Giant Cell Arteritis Drugs Market?

A) Genentech, Inc., F. Hoffmann-La Roche Ltd, Biogen, Novartis AG, Aark Pharmaceuticals, Aetna Inc., Sartorius AG, Fresenius Kabi USA, Bio-Rad Laboratories, Inc and CELLTRION INC.

Q3) What are the regions covered in this report?

A) The global Giant Cell Arteritis Drugs Market report focuses on six major regions: North America, Latin America, Europe, Asia Pacific, the Middle East, and Africa

4) What are the Segments Coverd in this report?

A) The Giant Cell Arteritis Drugs market is segmented as Drug Class, Route of Administration, and Distribution Channel.

Contact Us -
Company Name: DataM Intelligence
Contact Person: Sai Kiran
Email: Sai.k@datamintelligence.com
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com

About Us -
DataM Intelligence is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology.
Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.

This release was published on openPR.